Compare BST & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BST | ARDX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | BST | ARDX |
|---|---|---|
| Price | $40.72 | $7.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $12.95 |
| AVG Volume (30 Days) | 103.1K | ★ 6.5M |
| Earning Date | 01-01-0001 | 02-19-2026 |
| Dividend Yield | ★ 10.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $398,234,000.00 |
| Revenue This Year | N/A | $22.65 |
| Revenue Next Year | N/A | $31.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 58.12 |
| 52 Week Low | $27.87 | $3.21 |
| 52 Week High | $44.50 | $8.22 |
| Indicator | BST | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 64.74 |
| Support Level | $39.80 | $6.73 |
| Resistance Level | $41.44 | $7.25 |
| Average True Range (ATR) | 0.58 | 0.57 |
| MACD | -0.03 | 0.13 |
| Stochastic Oscillator | 49.46 | 80.31 |
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.